19-24周妊娠子痫前期联合筛查后的妊娠管理
这项前瞻性观察研究纳入16254例单胎妊娠,在19-24周用母体因素联合MAP、UtA-PI、PlGF和sFlt-1计算子痫前期风险,将人群分为高危、中危和低危管理组。高危组需在24-31周密切监测血压和蛋白尿,中危组及高危组未分娩者在32周重新评估风险以决定32-35周监测,所有妊娠在36周再次评估以制定后续监测和分娩计划。
要点
- 19-24周联合筛查可将妊娠人群分层为24-31周需密切监测者和32周需重新评估者。
- 高危组约占人群1%,可包含约35%至100%的32周前子痫前期病例,取决于筛查指标组合。
- 32周重新评估人群约占10%至18%,可包含约79%至90%的32+0至35+6周子痫前期病例。
核心结论
- 在新型妊娠保健金字塔中,19-24周评估子痫前期风险可将人群分层为需在24-31周密切监测者和需在32周重新评估者。
研究设计与样本
- 前瞻性观察研究,纳入常规妊娠保健中于19-24周接受超声扫描的16254例单胎妊娠。
- 采用竞争风险模型,将子痫前期的分娩孕周先验分布与MAP、UtA-PI、PlGF和sFlt-1的 multiples of the median(MoM)值结合,计算患者特异性风险。
- 采用不同风险界值改变高危、中危和低危组的比例,并评估筛查对<32周和32+0至35+6周分娩子痫前期的性能。
主要发现
- 研究人群16254例单胎妊娠中,467例(2.9%) subsequently developed 子痫前期,其中23例<32周分娩、58例32+0至35+6周分娩、386例≥36周分娩。
- 采用<32周子痫前期风险>1/25和<36周子痫前期风险>1/150时,高危组约占总体人群1%。
- <32周子痫前期病例在高危组中的比例:母体因素+MAP筛查约35%,母体因素+MAP+UtA-PI筛查78%,母体因素+MAP+UtA-PI+PlGF(联合或不联合sFlt-1)筛查达100%。
- 需在32周重新评估风险的人群比例及32+0至35+6周子痫前期病例在该人群中的比例:母体因素+MAP筛查分别约18%和79%,母体因素+MAP+UtA-PI+PlGF(联合或不联合sFlt-1)筛查分别为10%和90%。
临床怎么用
- 高危组需在24-31周密切监测高血压和蛋白尿。
- 中危组连同高危组未分娩妊娠在32周重新评估子痫前期风险,以识别需在32-35周密切监测高血压和蛋白尿者。
- 所有妊娠在36周重新评估子痫前期风险,以制定进一步监测和分娩计划。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the patient-specific risk of pre-eclampsia (PE) at 19-24 weeks' gestation by maternal factors and combinations of mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and serum soluble fms-like tyrosine kinase-1 (sFlt-1). On the basis of the risk of PE, the women would be stratified into high-, intermediate- and low-risk management groups. The high-risk group would require close monitoring for high blood pressure and proteinuria at 24-31 weeks. The intermediate-risk group, together with the undelivered pregnancies from the high-risk group, would have reassessment of risk for PE at 32 weeks to identify those who would require close monitoring for high blood pressure and proteinuria at 32-35 weeks. All pregnancies would have reassessment of risk for PE at 36 weeks to define the plan for further monitoring and delivery. METHODS: This was a prospective observational study of women attending for an ultrasound scan at 19-24 weeks as part of routine pregnancy care. Patient-specific risks of delivery with PE at < 32 and at < 36 weeks' gestation were calculated using the competing-risks model to combine the prior distribution of gestational age at delivery with PE, obtained from maternal characteristics and medical history, with multiples of the median (MoM) values of MAP, UtA-PI, PlGF and sFlt-1. Different risk cut-offs were used to vary the proportion of the population stratified into high-, intermediate- and low-risk groups, and the performance of screening for delivery with PE at < 32 weeks' gestation and at 32 + 0 to 35 + 6 weeks was estimated. RESULTS: The study population of 16 254 singleton pregnancies included 467 (2.9%) that subsequently developed PE (23 delivered at < 32 weeks, 58 delivered at 32 + 0 to 35 + 6 weeks and 386 delivered at ≥ 36 weeks). Using a risk of > 1 in 25 for PE at < 32 weeks' gestation and risk of > 1 in 150 for PE at < 36 weeks, the proportion of the population stratified into the high-risk group was about 1% of the total, and the proportion of cases of PE at < 32 weeks' gestation contained within this high-risk group varied from about 35% with screening by maternal factors and MAP, to 78% with maternal factors, MAP and UtA-PI, and up to 100% with maternal factors, MAP, UtA-PI and PlGF, with or without sFlt-1. Similarly, the proportion of the population requiring reassessment of risk at 32 weeks' gestation and the proportion of cases of PE at 32 + 0 to 35 + 6 weeks contained within this population varied, respectively, from about 18% and 79% with screening by maternal factors and MAP, to 10% and 90% with maternal factors, MAP, UtA-PI and PlGF, with or without sFlt-1. CONCLUSION: In the new pyramid of pregnancy care, assessment of risk for PE at 19-24 weeks' gestation can stratify the population into those requiring intensive monitoring at 24-31 weeks and those in need of reassessment at 32 weeks. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Litwinska M, Syngelaki A, Wright A, et al. Management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks' gestation. Ultrasound Obstet Gynecol. 2018. PMID: 29943498. doi:10.1002/uog.19099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。